AORT (Artivion) ROCE %: -2.03% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AORT Artivion Inc AORT
80 GF Score
Price $27.12
GF Value $28.65
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Artivion ROCE %?

Artivion AORT +2.07% 80 ROCE % is -2.03% as of Jun. 2026. GuruFocus rates AORT with a GF Score™ of 80/100 and a GF Value™ of $28.65 (Fairly Valued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Artivion's annualized ROCE % for the quarter that ended in Jun. 2026 was -2.03%.

Artivion  (NYSE:AORT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Artivion ROCE % Related Terms

Artivion ROCE % Historical Data

* Premium members only.

The historical data trend for Artivion's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artivion ROCE % Chart

Artivion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.44 0.51 3.67 5.49

Artivion Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.69 6.83 6.21 2.90 -2.03
AORT
80GF Score
Artivion Inc AORT
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artivion ROCE % Calculation

Artivion's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=41.362/( ( (789.101 - 66.823) + (884.796 - 101.556) )/ 2 )
=41.362/( (722.278+783.24)/ 2 )
=41.362/752.759
=5.49 %

Artivion's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=-17.784/( ( (883.157 - 92.7) + (1071.934 - 106.931) )/ 2 )
=-17.784/( ( 790.457 + 965.003 )/ 2 )
=-17.784/877.73
=-2.03 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -2.03% mean?
Artivion (AORT) has a ROCE % of -2.03% as of Jun. 2026.
Is Artivion's ROCE % too high?
Artivion's current ROCE % is -2.03%. Overall, Artivion has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Artivion's ROCE % compare to IRMD and ATEC?
Artivion's ROCE % of -2.03% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.40, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artivion's current ROCE % is -2.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artivion stock overvalued right now?
Based on GuruFocus' analysis, Artivion (AORT) is currently considered Fairly Valued. The stock's GF Value™ is $28.65, compared to a current price of $27.12 — trading 5.3% below its estimated fair value. The current ROCE % is -2.03%. Artivion's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Artivion (AORT), the current ROCE % is -2.03% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Artivion (AORT) Overvalued in 2026?

Based on GuruFocus' analysis, Artivion stock appears to be undervalued. The current stock price of $27.12 is trading 5.3% below its estimated GF Value™ of $28.65. GuruFocus considers Artivion to be Fairly Valued.

Key valuation signals for AORT:

  • ROCE %: -2.03%
  • GF Value™: $28.65 vs. price of $27.12 (5.3% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the AORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Artivion Business Description

Other Exchanges CYL:Germany
Address 1655 Roberts Boulevard North West, Kennesaw, GA, USA, 30144
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
80GF Score

Get the complete analysis for AORT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.12
Price
$28.65
GF Value